The Sodium Iodide Symporter (NIS) and Potential Regulators in Normal, Benign and Malignant Human Breast Tissue

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Feb 2

PMID 21283523

Citations 20

Authors

James Ryan

Catherine E Curran

Emer Hennessy

John Newell

John C Morris

Michael J Kerin

Roisin M Dwyer

Affiliations

Soon will be listed here.

Abstract

Introduction: The presence, relevance and regulation of the Sodium Iodide Symporter (NIS) in human mammary tissue remains poorly understood. This study aimed to quantify relative expression of NIS and putative regulators in human breast tissue, with relationships observed further investigated in vitro.

Methods: Human breast tissue specimens (malignant n = 75, normal n = 15, fibroadenoma n = 10) were analysed by RQ-PCR targeting NIS, receptors for retinoic acid (RARα, RARβ), oestrogen (ERα), thyroid hormones (THRα, THRβ), and also phosphoinositide-3-kinase (PI3K). Breast cancer cells were treated with Retinoic acid (ATRA), Estradiol and Thyroxine individually and in combination followed by analysis of changes in NIS expression.

Results: The lowest levels of NIS were detected in normal tissue (Mean(SEM) 0.70(0.12) Log(10) Relative Quantity (RQ)) with significantly higher levels observed in fibroadenoma (1.69(0.21) Log(10)RQ, p<0.005) and malignant breast tissue (1.18(0.07) Log(10)RQ, p<0.05). Significant positive correlations were observed between human NIS and ERα (r = 0.22, p<0.05) and RARα (r = 0.29, p<0.005), with the strongest relationship observed between NIS and RARβ (r = 0.38, p<0.0001). An inverse relationship between NIS and PI3K expression was also observed (r = 0.21, p<0.05). In vitro, ATRA, Estradiol and Thyroxine individually stimulated significant increases in NIS expression (range 6-16 fold), while ATRA and Thyroxine combined caused the greatest increase (range 16-26 fold).

Conclusion: Although NIS expression is significantly higher in malignant compared to normal breast tissue, the highest level was detected in fibroadenoma. The data presented supports a role for retinoic acid and estradiol in mammary NIS regulation in vivo, and also highlights potential thyroidal regulation of mammary NIS mediated by thyroid hormones.

Citing Articles

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer.

Barbaro D, Campenni A, Forleo R, Lapi P Endocrine. 2023; 81(1):30-35.

PMID: 36928601 PMC: 10018599. DOI: 10.1007/s12020-023-03338-2.

Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions.

Lu M, Liu H, Zheng B, Sun S, Chen C Cancers (Basel). 2022; 14(20).

PMID: 36291901 PMC: 9600751. DOI: 10.3390/cancers14205117.

Expression of pendrin and NIS iodide transporters in human breast tumor and peri-tumoral tissue.

Arczewska K, Godlewska M, Krasuska W, Lyczkowska A, Kiedrowski M, Czarnocka B Arch Med Sci. 2022; 18(4):1041-1050.

PMID: 35832691 PMC: 9266960. DOI: 10.5114/aoms.2019.89980.

Hormonal Crosstalk Between Thyroid and Breast Cancer.

Halada S, Casado-Medrano V, Baran J, Lee J, Chinmay P, Bauer A Endocrinology. 2022; 163(7).

PMID: 35587175 PMC: 9653009. DOI: 10.1210/endocr/bqac075.

Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy.

Jhiang S, Sipos J Endocr Relat Cancer. 2021; 28(10):T167-T177.

PMID: 33974556 PMC: 8419015. DOI: 10.1530/ERC-21-0035.

References

Alotaibi H, Yaman E, Salvatore D, Di Dato V, Telkoparan P, Di Lauro R . Intronic elements in the Na+/I- symporter gene (NIS) interact with retinoic acid receptors and mediate initiation of transcription. Nucleic Acids Res. 2010; 38(10):3172-85. PMC: 2879507. DOI: 10.1093/nar/gkq023. View

Knostman K, McCubrey J, Morrison C, Zhang Z, Capen C, Jhiang S . PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer. 2007; 7:137. PMC: 1963336. DOI: 10.1186/1471-2407-7-137. View

Silva J, Dominguez G, Gonzalez-Sancho J, Garcia J, Silva J, Garcia-Andrade C . Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002; 21(27):4307-16. DOI: 10.1038/sj.onc.1205534. View

Wapnir I, van de Rijn M, Nowels K, Amenta P, Walton K, Montgomery K . Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003; 88(4):1880-8. DOI: 10.1210/jc.2002-021544. View

Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M . The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003; 24(1):48-77. DOI: 10.1210/er.2001-0029. View

Moon D, Lee S, Park K, Park K, Ahn S, Pai M . Correlation between 99mTc-pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol. 2001; 28(7):829-34. DOI: 10.1016/s0969-8051(01)00243-8. View

Kogai T, Kanamoto Y, Li A, Che L, Ohashi E, Taki K . Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. Endocrinology. 2005; 146(7):3059-69. DOI: 10.1210/en.2004-1334. View

Riesco-Eizaguirre G, Santisteban P . A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006; 155(4):495-512. DOI: 10.1530/eje.1.02257. View

McNeill R, Miller N, Kerin M . Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol. 2007; 8:107. PMC: 2211316. DOI: 10.1186/1471-2199-8-107. View

10.

Berger F, Unterholzner S, Diebold J, Knesewitsch P, Hahn K, Spitzweg C . Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma. Biochem Biophys Res Commun. 2006; 349(4):1258-63. DOI: 10.1016/j.bbrc.2006.08.170. View

11.

Lee S, Privalsky M . Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties. Mol Endocrinol. 2005; 19(4):863-78. PMC: 2675561. DOI: 10.1210/me.2004-0210. View

12.

Nagaya T, Jameson J . Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem. 1993; 268(21):15766-71. View

13.

Renier C, Yao C, Goris M, Ghosh M, Katznelson L, Nowles K . Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol. 2009; 16(4):962-8. DOI: 10.1245/s10434-008-0280-9. View

14.

Ohashi E, Kogai T, Kagechika H, Brent G . Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res. 2009; 69(8):3443-50. PMC: 2852426. DOI: 10.1158/0008-5472.CAN-08-3234. View

15.

Barton K, Stricker H, Brown S, Elshaikh M, Aref I, Lu M . Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008; 16(10):1761-9. PMC: 3127288. DOI: 10.1038/mt.2008.172. View

16.

Wapnir I, Goris M, Yudd A, Dohan O, Adelman D, Nowels K . The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004; 10(13):4294-302. DOI: 10.1158/1078-0432.CCR-04-0074. View

17.

Dohan O, Carrasco N . Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol. 2004; 213(1):59-70. DOI: 10.1016/j.mce.2003.10.059. View

18.

Castro M, Bergert E, Beito T, McIver B, Goellner J, Morris J . Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab. 1999; 84(8):2957-62. DOI: 10.1210/jcem.84.8.5871. View

19.

Knostman K, Cho J, Ryu K, Lin X, McCubrey J, Hla T . Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab. 2004; 89(10):5196-203. DOI: 10.1210/jc.2004-0907. View

20.

Wallden B, Emond M, Swift M, Disis M, Swisshelm K . Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells. BMC Cancer. 2005; 5:140. PMC: 1283145. DOI: 10.1186/1471-2407-5-140. View